N. Becker, H. Altenburg, C. Stegmaier, and H. Ziegler, Report on trends of incidence (1970???2002) of and mortality (1952???2002) from cancer in Germany, Journal of Cancer Research and Clinical Oncology, vol.88, issue.1, pp.23-35, 2007.
DOI : 10.1007/s00432-006-0142-4

M. Center, A. Jemal, and E. Ward, International Trends in Colorectal Cancer Incidence Rates, Cancer Epidemiology Biomarkers & Prevention, vol.18, issue.6, pp.1688-1694, 2009.
DOI : 10.1158/1055-9965.EPI-09-0090

R. Cress, C. Morris, G. Ellison, and M. Goodman, Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ethnicity, 1992???2001, Cancer, vol.109, issue.S5, pp.1142-1152, 1992.
DOI : 10.1002/cncr.22011

B. Edwards, E. Ward, B. Kohler, C. Eheman, A. Zauber et al., Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates, Annual report to the nation on the status of cancer, pp.544-573, 1975.
DOI : 10.1002/cncr.24760

H. Karim-kos, V. De, I. Soerjomataram, V. Lemmens, S. Siesling et al., Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s, European Journal of Cancer, vol.44, issue.10, pp.1345-1389, 2008.
DOI : 10.1016/j.ejca.2007.12.015

A. Jemal, R. Siegel, J. Xu, and E. Ward, Cancer Statistics, 2010, CA: A Cancer Journal for Clinicians, vol.60, issue.5, pp.277-300, 2010.
DOI : 10.3322/caac.20073

C. Evans, A. Dalgleish, and D. Kumar, Review article: immune suppression and colorectal cancer, Alimentary Pharmacology and Therapeutics, vol.293, issue.2, pp.1163-1177, 2006.
DOI : 10.1007/BF01741090

T. Kemp, A. Ludwig, J. Earel, J. Moore, R. Vanoosten et al., Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L, Blood, vol.106, issue.10, pp.3474-3482, 2005.
DOI : 10.1182/blood-2005-03-1327

C. Manegold, D. Gravenor, D. Woytowitz, J. Mezger, V. Hirsh et al., Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.26, issue.24, pp.3979-3986, 2008.
DOI : 10.1200/JCO.2007.12.5807

D. Mauri, K. Kamposioras, L. Tsali, M. Bristianou, A. Valachis et al., Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis, Cancer Treatment Reviews, vol.36, issue.1, pp.69-74, 2010.
DOI : 10.1016/j.ctrv.2009.10.006

B. Keogh and A. Parker, Toll-like receptors as targets for immune disorders, Trends in Pharmacological Sciences, vol.32, issue.7, pp.435-442, 2011.
DOI : 10.1016/j.tips.2011.03.008

C. Cluff, Monophosphoryl Lipid A (MPL) as an Adjuvant for Anti-Cancer Vaccines: Clinical Results, Adv Exp Med Biol, vol.667, pp.111-123, 2009.
DOI : 10.1007/978-1-4419-1603-7_10

E. Palsson-mcdermott, O. Neill, and L. , Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4, Immunology, vol.169, issue.2, pp.153-162, 2004.
DOI : 10.1038/35085597

H. Inagawa, T. Nishizawa, K. Noguchi, M. Minamimura, K. Takagi et al., Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system, Anticancer Res, vol.17, pp.2153-2158, 1997.

J. Jeannin, N. Onier, P. Lagadec, J. Von, P. Stutz et al., Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat, Gastroenterology, vol.101, issue.3, pp.726-733, 1991.
DOI : 10.1016/0016-5085(91)90532-P

N. Onier, S. Hilpert, L. Arnould, V. Saint-giorgio, J. Davies et al., Cure of colon cancer metastasis in rats with the new lipid A OM 174 Apoptosis of tumor cells and immunization of rats, Clinical & Experimental Metastasis, vol.17, issue.4, pp.299-306, 1999.
DOI : 10.1023/A:1006663017149

I. Parr, E. Wheeler, and A. P. , Similarities of the Anti-tumour Actions of Endotoxin, Lipid A and Double-stranded RNA, British Journal of Cancer, vol.27, issue.5, pp.370-389, 1973.
DOI : 10.1038/bjc.1973.45

N. Sassi, C. Paul, A. Martin, A. Bettaieb, and J. Jeannin, Lipid A induced response in vivo.InLipid A in cancer therapy, Edited by Jeannin J, vol.2010, pp.69-80

C. Blondiau, P. Lagadec, P. Lejeune, N. Onier, J. Cavaillon et al., Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopolysaccharides from different bacterial species, Immunobiology, vol.190, issue.3, pp.243-254, 1994.
DOI : 10.1016/S0171-2985(11)80272-X

P. Van-de-wiel, P. Van-der, and N. Bloksma, Role of tumour necrosis factor in the tumour-necrotizing activity of agents with diverging toxicity, Cancer Immunology, Immunotherapy, vol.39, issue.2, pp.115-120, 1991.
DOI : 10.1007/BF01742539

D. Reisser, A. Pance, and J. Jeannin, Mechanisms of the antitumoral effect of lipid A, BioEssays, vol.22, issue.3, pp.284-289, 2002.
DOI : 10.1002/bies.10053

N. Onier, P. Lejeune, M. Martin, A. Hammann, J. Bauer et al., Involvement of T lymphocytes in curative effect of a new immunomodulator OM 163 on rat colon cancer metastases, European Journal of Cancer, vol.29, issue.14, pp.2003-2009, 1993.
DOI : 10.1016/0959-8049(93)90462-O

T. Shimizu, K. Iida, Y. Iwamoto, Y. Yanagihara, K. Ryoyama et al., Biological activities and antitumor effects of synthetic lipid a analog linked n-acylated serine, International Journal of Immunopharmacology, vol.17, issue.5, pp.425-431, 1995.
DOI : 10.1016/0192-0561(95)00014-S

D. Agostini, C. Pica, F. Febbraro, G. Grelli, S. Chiavaroli et al., Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions, International Immunopharmacology, vol.5, issue.7-8, pp.1205-1212, 2005.
DOI : 10.1016/j.intimp.2005.02.013

A. Kiani, A. Tschiersch, E. Gaboriau, F. Otto, A. Seiz et al., Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients, pp.1673-1683, 1997.

J. De-bono, A. Dalgleish, J. Carmichael, J. Diffley, F. Lofts et al., Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide, Clin Cancer Res, vol.6, pp.397-405, 2000.

G. Vosika, C. Barr, and D. Gilbertson, Phase-I study of intravenous modified lipid A, Cancer Immunology Immunotherapy, vol.18, issue.2, pp.107-112, 1984.
DOI : 10.1007/BF00205743

P. Rickham, Human experimentation Code of ethics of the World Medical Association. Declaration of Helsinki, Br Med J, vol.2, p.177, 1964.

P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan et al., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-216, 2000.
DOI : 10.1093/jnci/92.3.205

F. Lirussi, Z. Rakotoniaina, S. Madani, F. Goirand, M. Breuiller-fouche et al., ADRB3 Adrenergic Receptor Is a Key Regulator of Human Myometrial Apoptosis and Inflammation During Chorioamnionitis1, Biology of Reproduction, vol.78, issue.3, pp.497-505, 2008.
DOI : 10.1095/biolreprod.107.064444

C. Prunet, T. Montange, A. Vejux, A. Laubriet, J. Rohmer et al., Multiplexed flow cytometric analyses of pro-and antiinflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients, Cytometry A, vol.69, pp.359-373, 2006.

D. Ducloux, M. Deschamps, M. Yannaraki, C. Ferrand, J. Bamoulid et al., Relevance of Toll-like receptor-4 polymorphisms in renal transplantation, Kidney International, vol.67, issue.6, pp.2454-2461, 2005.
DOI : 10.1111/j.1523-1755.2005.00354.x

M. Ellegaard, L. Bastholt, A. Jakobsen, F. Donskov, and H. Schmidt, Interleukin-2-induced fever in relation to objective tumor response and survival in patients with metastatic melanoma., Journal of Clinical Oncology, vol.28, issue.15_suppl, p.15, 2010.
DOI : 10.1200/jco.2010.28.15_suppl.8569

R. Engelhardt, A. Mackensen, and C. Galanos, Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients, Cancer Res, vol.51, pp.2524-2530, 1991.

C. Rockwell, D. Morison, and N. Qureshi, Lipid A-Mediated Tolerance and Cancer Therapy, In Lipid A in cancer therapy. Edited by Jeannin J, vol.2010, pp.81-99
DOI : 10.1007/978-1-4419-1603-7_8

R. Garay, P. Viens, J. Bauer, G. Normier, M. Bardou et al., Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help, European Journal of Pharmacology, vol.563, issue.1-3, pp.1-17, 2007.
DOI : 10.1016/j.ejphar.2007.02.018